QuickView: Becoming more than BioThrax
Emergent is transforming, largely through integrating Cangene, acquired in February 2014, with its three Biodefense and four specialty Biosciences products. Revenue guidance for FY14 is $445m-$450m (GAAP net income $36m-$38m) and 2015 guidance is for total revenues of $510m-$540m. The company continues to actively expand its Biodefense portfolio to exploit the $5bn-$6bn annual US government spend and to acquire products that add revenues in Biosciences. Further M&A activity, plus clarity on IXinity approval and a partner for otlertuzumab should provide interest in 2015.Emergent BioSolutions is a life sciences company. The company is focused on preparedness and response products and solutions that address the following categories: Chemical, Biological, Radiological, Nuclear and Explosives; emerging infectious diseases; travel health; emerging health crises; acute/emergency care; and contract development and manufacturing. The company also has a development pipeline consisting of a mix of both pre-clinical and clinical-stage product candidates, including Trobigard? a combination drug-device auto injector product candidate. In addition, the company has a fully integrated molecule-to-market biologics CDMO business offerings (development services, drug substance and drug product).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.